Recommended

New webinar: Overcoming critical challenges in AI-driven drug discovery
Watch on demand: Rapid cell-based profiling of multi-target anti-obesity drugs Watch here!
Download now: Unlock the power of stem cell therapy and discover the potential for new therapies for primary open-angle glaucoma
Brand new Beyond the Lab report on antibodies… Download NOW!
article

The growth of cell line development

The rising number of biologics approved for therapeutic use has placed an emphasis on safe and efficient production lines. Here, Drug Target Review’s Editor Victoria Rees considers why biotherapeutic development is likely to prompt significant growth for the cell line market in the next decade.

Stable cell lines are used for a wide variety of applications, including the development of gene functional research, drug screening and biologics. Many blockbuster drugs contain biologics, revealing the significance of recent cell line innovations to support the safe development of biotherapeutics. Each year, the number of biologics available to patients continues to rise, including monoclonal antibodies (mAbs), vaccines, hormones and other proteins. All of these have a wide range of applications in the pharmaceutical industry such as therapeutics and diagnostics, further highlighting the importance of ensuring reliable cell lines are available to the industry.

According to a new report, the global biotherapeutic cell line market was worth around $108.7 million in 2019 and it is expected to grow at a compound annual growth rate (CAGR) of 6.9 percent during the forecast period to reach $223.7 million by 2030.1 Over the past few decades, researchers across academia and industry have focused on resolving the flaws in the initial compositions and ensuring…